Flu Pandemic Plan: Financial Incentives To Increase Manufacturing Capacity
This article was originally published in The Pink Sheet Daily
Executive Summary
HHS plans to increase its demand for influenza vaccine to strengthen the vaccine delivery system and expand manufacturing capacity, a draft document states. Use of adjuvants could expand the vaccine supply, HHS suggests.
You may also be interested in...
FluMist May Require Additional Phase III Trial To Expand Patient Population
MedImmune seeks to expand the indication for its intranasal flu vaccine to people ages 50 to 64; the company is waiting to see if FDA will accept new analyses of existing data in the target age group. MedImmune and Chiron suggest incentives to increase flu vaccine demand during a House committee hearing.
FluMist May Require Additional Phase III Trial To Expand Patient Population
MedImmune seeks to expand the indication for its intranasal flu vaccine to people ages 50 to 64; the company is waiting to see if FDA will accept new analyses of existing data in the target age group. MedImmune and Chiron suggest incentives to increase flu vaccine demand during a House committee hearing.
HHS Pandemic Response Plan Could Be Hindered By SEC Regulations
HHS' efforts to increase manufacturing capacity to prepare for an influenza pandemic could be affected if manufacturers are unable to record stockpile revenue under Securities & Exchange Commission regulations